查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929535

生技药品CXO服务市场按服务模式、治疗领域、临床阶段、应用和最终用户划分，全球预测（2026-2032年）

Biologics CXO Services Market by Service Model, Therapeutic Area, Clinical Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年生物製剂 CXO 服务市值为 5.8021 亿美元，预计到 2026 年将成长至 6.2493 亿美元，复合年增长率为 7.06%，到 ​​2032 年将达到 9.3584 亿美元。

关键市场统计数据
基准年 2025 5.8021亿美元
预计年份：2026年 6.2493亿美元
预测年份 2032 9.3584亿美元
复合年增长率 (%) 7.06%

本书简明扼要地全面介绍了由科学创新、监管复杂性和策略外包共同塑造的、不断发展的生物製药合约服务生态系统。

生物製药合约服务产业正演变为一个复杂的生态系统，科学创新、监管细则和规模经济在此交汇融合。包括製造商、服务供应商、申办者和研究机构在内的相关人员，正在药物发现、开发和商业化过程中加强合作。这一趋势正在重塑人们对外包活动的速度、品质和合规性的预期，使得合作伙伴的选择和能力匹配具有重要的策略意义。

透过证据检验美国近期关税措施对生物製药计画供应链韧性、营运成本和策略采购决策的影响。

近期贸易政策调整带来的发展趋势，为跨境生物製药研发和供应机构的营运带来了新的复杂性。关税带来的成本压力在关键原料、一次性组件和分析试剂的运输中尤为显着，迫使采购团队重新评估供应商组合，并探索能够维持供应连续性和品质标准的替代筹资策略。同时，海关延误可能会加剧临床试验启动时间和产品上市时间的风险，尤其对于那些依赖临床和生产基地之间紧密协调的物流的专案而言。

关键细分洞察揭示了服务模式专业化、治疗方法、临床阶段、最终用户类型和公司规模如何影响合作伙伴的选择和能力要求。

深入分析市场细分，可以发现能力、专案阶段和最终用户优先级等因素交织，共同塑造了服务需求。以服务模式分析市场发现，产品和服务分布在CDMO、CMO和CRO三大领域。 CDMO的专业技术往往集中在分析测试、生产製造、製程开发和法规咨询方面。 CMO通常专注于临床和商业化生产，而CRO的核心服务则包括临床试验管理、药物监测和临床前服务。这种分层服务结构凸显了服务提供者既需要在各个技术领域展现深厚的专业知识，也需要具备支援多阶段开发计画所需的协调能力。

区域动态和能力丛集对关键区域的合作伙伴选择、临床试验准入、监管协调和生产本地化产生影响

区域趋势反映了人才供应、法规环境和基础设施的差异，从而重塑了投资和伙伴关係的发生地点。在美洲，成熟的生态系统将成熟的生物製造能力与密集的临床试验中心网络和监管专业知识相结合，为高度复杂的项目和快速的临床转化提供了支持。儘管该地区仍然是创新中心，但也面临更高的营运成本以及对熟练的生产和品管人员的激烈竞争。

对公司能力和竞争差异化趋势的描述，阐述了技术深度、监管专业知识和综合服务模式如何奠定市场领导地位。

在生物製剂合约服务领域，各公司之间的竞争日益取决于技术实力的深度、平台的扩充性以及在研发各阶段提供整合服务的能力。主要企业透过投资先进的分析技术、模组化生产平台以及能够应对跨国申报的法规咨询团队来脱颖而出。同样重要的是品质系统和资料管治实务的完善程度，客户要求在整个外包合作关係中保持透明的可追溯性和强大的审核能力。

为产业领导者提供切实可行的建议，以加强生物製剂专案的供应链韧性、加速技术能力融合併提升客户合作

产业领导者应优先考虑增强供应链韧性、加速跨模式技术整合以及提升以客户为中心的服务水准。首先，应将贸易中断、原材料短缺和监管变化等情境规划纳入采购和供应链管治，以降低专案脆弱性。这包括供应商多元化、建构跨区域冗余以及规范监管沟通的变更管理流程。

严谨的混合调查方法结合了关键相关人员访谈、监管和技术文献综述以及三角验证的定性分析，确保了研究结果的可靠性。

该研究采用混合方法进行综合分析，结合了对主要相关人员的访谈、对技术和监管指南的二次审查，以及对公开文件和科学文献的定性分析。主要工作包括与生产和临床营运经理、品质和监管专家以及研发经理进行结构化讨论，以收集第一线观点对能力差距、投资重点和合作伙伴选择标准的看法。此外，还对监管指导文件和同行评审的研究文章进行了重点审查，以确保技术准确性并检验新兴趋势。

在不断发展的生物製剂服务环境中，对决定合作伙伴选择和专案成功的策略重点和能力要求进行综合分析。

总而言之，生物製药合约服务生态系统正日趋成熟，成为一个策略性、协作性的网络，其中技术能力、监管敏锐度和供应链韧性决定着专案的成功。细胞和基因疗法的技术进步，以及不断变化的监管预期，正在催生对涵盖药物发现到商业化生产的一体化服务模式的需求。区域能力丛集和关税相关的贸易考量正在重塑采购决策，促使企业采用更完善的风险管理和在地化策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章生技药品CXO服务市场依服务模式划分

  • CDMO
    • 分析测试
    • 製造业
    • 製程开发
    • 监理咨询
  • CMO
    • 临床生产
    • 商业生产
  • CRO
    • 临床试验管理
    • 药物安全检测
    • 非临床试验服务

第九章生技药品CXO服务市场（依治疗领域划分）

  • 自体免疫疾病
  • 循环系统
  • 感染疾病
  • 神经病学
  • 肿瘤学

第十章生技药品CXO服务市场（依临床阶段划分）

  • 商业的
  • 勘探阶段
  • I期试验
  • 第二阶段
  • 第三阶段
  • 临床前

第十一章生技药品CXO服务市场（依应用领域划分）

  • 细胞疗法
  • 基因治疗
  • 单株抗体
  • 重组蛋白
  • 疫苗

第十二章生技药品CXO服务市场（依最终用户划分）

  • 学术机构
  • 生物製药公司
  • 研究所

第十三章生技药品CXO服务市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章生技药品首席体验长 (CXO) 服务市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国生技药品高阶主管服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国生技药品首席体验长 (CXO) 服务市场

第十七章：中国生技药品高阶主管服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AGC Biologics
  • AGC Inc.
  • Alvotech hf.
  • BioVectra Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Curia Global, Inc.
  • Fujifilm Holdings Corporation
  • Hikma Pharmaceuticals PLC
  • Lonza Group AG
  • Merck KGaA
  • Novasep Holding SAS
  • Patheon Biologics
  • Piramal Pharma Solutions
  • Polpharma Biologics
  • PTC Bio, Inc.
  • Recipharm AB
  • Richter-Helm Biologics GmbH & Co. KG
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma International GmbH
  • WuXi Biologics Inc.
  • Xellia Pharmaceuticals A/S
Product Code: MRR-0A3806951800

The Biologics CXO Services Market was valued at USD 580.21 million in 2025 and is projected to grow to USD 624.93 million in 2026, with a CAGR of 7.06%, reaching USD 935.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 580.21 million
Estimated Year [2026] USD 624.93 million
Forecast Year [2032] USD 935.84 million
CAGR (%) 7.06%

A concise yet comprehensive introduction to the evolving biologics contract services ecosystem shaped by scientific innovation, regulatory complexity, and strategic outsourcing

The biologics contract services landscape is evolving into a complex ecosystem where scientific innovation, regulatory nuance, and operational scale converge. Stakeholders including manufacturers, service providers, sponsors, and research institutions are navigating tighter integration between discovery, development, and commercialization pathways. This dynamic is reshaping expectations for speed, quality, and compliance across outsourced activities, elevating the strategic importance of partner selection and capability alignment.

As organizations pursue advanced modalities such as cell and gene therapies alongside traditional monoclonal antibodies and recombinant proteins, service providers are compelled to broaden their technical depth while maintaining rigorous quality systems. Investment decisions are increasingly influenced by the ability to support multi-phase programs, deliver analytical and process development expertise, and provide regulatory consulting that anticipates global expectations. The evolving buyer-supplier relationship emphasizes collaboration over transactional procurement, with an emphasis on co-development, IP protection, and flexible commercial models.

The industry is undergoing transformative shifts that are redefining how biologics are developed and brought to market. Technological advances in cell and gene therapies are driving demand for specialized capabilities in vector manufacturing, cell processing, and potency assays, while high-throughput analytical platforms and single-use technologies are enabling faster scale-up and reduced cross-contamination risk. Concurrently, regulatory agencies are issuing more detailed guidance on comparability, control strategies, and long-term safety monitoring, prompting service providers to invest in robust quality systems and enhanced data integrity solutions.

Commercial considerations are also in flux as sponsors seek partners capable of spanning early-stage development through commercial supply. This has incentivized consolidation and strategic partnerships across CDMOs, CMOs, and CROs to create vertically integrated offerings. Geographic diversification of supply chains is accelerating as organizations hedge regional risks and pursue proximity to clinical trial sites and manufacturing talent pools. Overall, the landscape is moving towards end-to-end service models, closer scientific collaboration, and stronger emphasis on digitalization to enable traceability, predictive maintenance, and remote oversight.

An evidence-based examination of how recent United States tariff actions are influencing supply chain resilience, operational costs, and strategic sourcing decisions across biologics programs

Recent tariff developments originating from trade policy adjustments have introduced a new layer of operational complexity for organizations engaged in cross-border biologics development and supply. Tariff-driven cost pressures are most apparent in the movement of critical raw materials, single-use components, and analytical reagents, requiring procurement teams to reassess supplier portfolios and to seek alternative sourcing strategies that preserve supply continuity and quality standards. In parallel, customs-related delays can amplify time-to-clinic and time-to-market risks for programs that depend on tightly choreographed logistics between clinical sites and manufacturing facilities.

Strategically, teams are reallocating inventory buffers and exploring regionalization of certain manufacturing steps to reduce exposure to tariff volatility and to maintain control over validated supply chains. Regulatory considerations become salient when substituting suppliers or materials, as comparability data may be needed to satisfy authorities. Service providers and sponsors are responding by strengthening contractual terms, enhancing transparency around cost pass-through mechanisms, and integrating tariff scenario planning into their risk management frameworks to safeguard program timelines and product integrity.

Key segmentation insights that reveal how service model specialization, therapeutic modality, clinical stage, end-user type, and company size drive partner selection and capability requirements

A nuanced view of segmentation reveals where capabilities, program stages, and end-user priorities intersect to shape service demand. When examining the market by service model, offerings are distributed across CDMO, CMO, and CRO frameworks; within CDMOs, specialization often clusters around analytical testing, manufacturing, process development, and regulatory consulting, while CMOs are typically focused on clinical manufacturing and commercial manufacturing, and CROs center on clinical trial management, pharmacovigilance, and preclinical services. This layered service architecture underscores the need for providers to demonstrate both depth in discrete technical domains and the orchestration skills required to support multi-phase development timelines.

Application-driven segmentation highlights modality-specific requirements. Cell therapy initiatives require end-to-end support spanning discovery through commercial supply, with critical dependencies on closed-system processing, chain-of-identity controls, and potency assays. Gene therapy programs demand vector manufacturing, delivery analytics, and long-term biodistribution studies across clinical stages. Monoclonal antibodies and recombinant proteins share a reliance on scalable upstream and downstream processes coupled with advanced analytical characterization. Vaccines present distinct cold-chain and fill-finish challenges that intersect with public health imperatives. Therapeutic area segmentation emphasizes different regulatory and clinical paradigms; oncology development pathways often prioritize accelerated timelines and biomarker-driven endpoints, whereas infectious disease programs emphasize population-scale manufacturing and global distribution considerations. Clinical-stage segmentation clarifies how needs evolve from discovery to preclinical and through phased clinical development into commercial supply, and end-user segmentation differentiates priorities among academia, biopharmaceutical companies, and research institutions. Company-size segmentation further differentiates expectations; large pharmaceutical organizations tend to require global supply continuity and extensive compliance documentation, mid-size firms balance flexibility with scale, and small biotech sponsors often prioritize agility, cost containment, and partner-led regulatory navigation.

Regional dynamics and capability clusters that influence partner selection, clinical trial access, regulatory alignment, and manufacturing localization across major geographies

Regional dynamics are reshaping where investments and partnerships materialize, reflecting differences in talent availability, regulatory environments, and infrastructure. In the Americas, a mature ecosystem combines established biomanufacturing capacity with a dense network of clinical sites and regulatory expertise, which supports high-complexity programs and rapid clinical translation. This region remains a hub for innovation, yet it also contends with higher operational costs and competitive demand for skilled manufacturing and quality personnel.

Europe, Middle East & Africa present a heterogeneous landscape where pockets of advanced capability coexist with markets that are rapidly scaling. European centers of excellence are notable for regulatory alignment across neighboring countries, well-developed GMP facilities, and a strong talent pipeline in biologics analytics. Emerging markets in the Middle East and Africa are increasingly attractive for clinical trials and certain manufacturing activities due to cost advantages, yet they require careful regulatory and logistical planning. Asia-Pacific is characterized by fast-growing manufacturing capacity, competitive cost structures, and substantial investments in cell and gene therapy capabilities. Several Asian markets are developing specialized clusters for biologics production and process innovation, which is driving increased collaboration with global sponsors and accelerating regional self-sufficiency for certain modalities.

Corporate capability narratives and competitive differentiation trends demonstrating how technical depth, regulatory expertise, and integrated service models define market leadership

Competitive positioning among companies operating in the biologics contract services space is increasingly defined by depth of technical capabilities, platform scalability, and the ability to deliver integrated services across development stages. Leading service providers differentiate through investments in advanced analytics, modular manufacturing platforms, and regulatory consulting teams capable of navigating multinational submissions. Equally important is the strength of quality systems and data governance practices, as clients demand transparent traceability and robust audit readiness across outsourced relationships.

Strategic partnerships, mergers, and targeted capacity expansions are common tactics companies use to fill capability gaps and to accelerate time-to-service for sponsors. Firms that cultivate cross-functional teams able to manage complex comparability exercises, implement process intensification, and support potency and safety testing stand to capture higher-value engagements. At the same time, nimble specialized providers retain appeal for early-stage sponsors seeking bespoke process development, rapid iteration, and close technical collaboration. Investors and business development teams are therefore evaluating not only physical assets but also intangible assets such as scientific talent, regulatory track record, and the flexibility of commercial terms.

Actionable recommendations for industry leaders to enhance supply resilience, accelerate technical capability convergence, and strengthen client alignment across biologics programs

Industry leaders should prioritize actions that strengthen supply resilience, accelerate technical convergence across modalities, and improve client-centric service delivery. First, embedding scenario planning for trade disruptions, raw material constraints, and regulatory changes into procurement and supply chain governance will reduce program vulnerability. This includes diversifying validated suppliers, creating redundancy across regions, and codifying change control pathways that anticipate regulatory engagement.

Second, investing in platform technologies that enable modular scale-up, digital batch records, and predictive maintenance will shorten development timelines and improve reproducibility. Training and talent development programs that bridge process engineering, analytical science, and regulatory strategy will increase organizational agility. Finally, adopting flexible commercial models-such as risk-sharing agreements and milestone-linked pricing-can align incentives between sponsors and providers, fostering long-term partnerships. Cultivating transparent communication channels and offering tailored regulatory support will enhance trust and position providers as strategic collaborators rather than transactional vendors.

Rigorous mixed-methods research methodology combining primary stakeholder interviews, regulatory and technical literature review, and triangulated qualitative analysis to ensure robust insights

The research synthesis presented here draws on a mixed-methods approach combining primary interviews with industry stakeholders, secondary review of technical and regulatory guidelines, and qualitative analysis of public filings and scientific literature. Primary engagement included structured discussions with manufacturing and clinical operations leaders, quality and regulatory experts, and R&D heads to capture firsthand perspectives on capability gaps, investment priorities, and partnership criteria. These interviews were complemented by a targeted review of regulatory guidance documents and peer-reviewed studies to ensure technical accuracy and to validate emerging trends.

Analytical rigor was maintained by triangulating findings across multiple sources and by applying scenario analysis to assess operational and strategic implications. Care was taken to anonymize proprietary inputs and to synthesize themes that reflect consensus and divergence among stakeholders. Limitations of the methodology are acknowledged, including the dynamic nature of policy and technological adoption and the potential for rapid shifts driven by clinical successes or supply chain disruptions. Nevertheless, the combination of qualitative insights and document analysis provides a robust foundation for the strategic observations and recommendations articulated in this report.

Concluding synthesis of strategic priorities and capability imperatives that will determine partner selection and program success in the evolving biologics services landscape

In summary, the biologics contract services ecosystem is maturing into a strategic, collaborative network where technical capability, regulatory acumen, and supply chain resilience determine successful program outcomes. Technological advances in cell and gene therapies, coupled with evolving regulatory expectations, are creating demand for integrated service models that span discovery through commercial manufacturing. Regional capability clusters and tariff-related trade considerations are reshaping sourcing decisions and prompting firms to adopt more sophisticated risk management and localization strategies.

For stakeholders across academia, biotech, and large pharmaceutical companies, the choice of partner increasingly reflects a balance between scientific expertise, operational reliability, and contractual flexibility. Providers that can demonstrate end-to-end capability, maintain high-quality data governance, and collaborate effectively on regulatory strategy will be best positioned to support complex biologics programs. Continued investment in talent, digital tools, and adaptable manufacturing platforms will be essential to meet the accelerating technical and commercial demands of the sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics CXO Services Market, by Service Model

  • 8.1. CDMO
    • 8.1.1. Analytical Testing
    • 8.1.2. Manufacturing
    • 8.1.3. Process Development
    • 8.1.4. Regulatory Consulting
  • 8.2. CMO
    • 8.2.1. Clinical Manufacturing
    • 8.2.2. Commercial Manufacturing
  • 8.3. CRO
    • 8.3.1. Clinical Trial Management
    • 8.3.2. Pharmacovigilance
    • 8.3.3. Preclinical Services

9. Biologics CXO Services Market, by Therapeutic Area

  • 9.1. Autoimmune
  • 9.2. Cardiology
  • 9.3. Infectious Diseases
  • 9.4. Neurology
  • 9.5. Oncology

10. Biologics CXO Services Market, by Clinical Stage

  • 10.1. Commercial
  • 10.2. Discovery
  • 10.3. Phase I
  • 10.4. Phase II
  • 10.5. Phase III
  • 10.6. Preclinical

11. Biologics CXO Services Market, by Application

  • 11.1. Cell Therapy
  • 11.2. Gene Therapy
  • 11.3. Monoclonal Antibodies
  • 11.4. Recombinant Proteins
  • 11.5. Vaccines

12. Biologics CXO Services Market, by End User

  • 12.1. Academia
  • 12.2. Biopharmaceutical Companies
  • 12.3. Research Institutions

13. Biologics CXO Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biologics CXO Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biologics CXO Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biologics CXO Services Market

17. China Biologics CXO Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AGC Biologics
  • 18.6. AGC Inc.
  • 18.7. Alvotech hf.
  • 18.8. BioVectra Inc.
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Catalent, Inc.
  • 18.11. Curia Global, Inc.
  • 18.12. Fujifilm Holdings Corporation
  • 18.13. Hikma Pharmaceuticals PLC
  • 18.14. Lonza Group AG
  • 18.15. Merck KGaA
  • 18.16. Novasep Holding SAS
  • 18.17. Patheon Biologics
  • 18.18. Piramal Pharma Solutions
  • 18.19. Polpharma Biologics
  • 18.20. PTC Bio, Inc.
  • 18.21. Recipharm AB
  • 18.22. Richter-Helm Biologics GmbH & Co. KG
  • 18.23. Samsung Biologics Co., Ltd.
  • 18.24. Sartorius AG
  • 18.25. Siegfried Holding AG
  • 18.26. Thermo Fisher Scientific Inc.
  • 18.27. Vetter Pharma International GmbH
  • 18.28. WuXi Biologics Inc.
  • 18.29. Xellia Pharmaceuticals A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CXO SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS CXO SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHARMACOVIGILANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHARMACOVIGILANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHARMACOVIGILANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ACADEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ACADEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)